1. Home
  2. RDI vs SNTI Comparison

RDI vs SNTI Comparison

Compare RDI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.05

Market Cap

24.1M

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.94

Market Cap

22.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
SNTI
Founded
1937
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1M
22.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RDI
SNTI
Price
$1.05
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.00
AVG Volume (30 Days)
27.6K
164.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.42
$150.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.80
52 Week High
$1.65
$5.10

Technical Indicators

Market Signals
Indicator
RDI
SNTI
Relative Strength Index (RSI) 45.96 47.44
Support Level $1.00 $0.80
Resistance Level $1.16 $1.19
Average True Range (ATR) 0.06 0.07
MACD -0.00 0.02
Stochastic Oscillator 55.81 64.70

Price Performance

Historical Comparison
RDI
SNTI

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Share on Social Networks: